Compare
Darzalex vs. Sarclisa

Darzalex (daratumumab) is an anti-CD38 monoclonal antibody. It's used to treat multiple myeloma in adults, often in combination with other anticancer medications. Darzalex (daratumumab) is given as an intravenous infusion through your vein (IV). Typically, you receive it every week or every few weeks, depending on where you are in the treatment process. Some common side effects of Darzalex (daratumumab) include infusion-related reactions, higher risk of infection, and feeling tired.

• Adults newly diagnosed with multiple myeloma (MM), but not able to receive stem cell transplant (in combination with other anticancer medications)
• Adults newly diagnosed with MM and able to receive stem cell transplant (in combination with other anticancer medications)
• Adults with advanced MM who already received but didn’t respond well to at least one prior anticancer treatment (in combination with other anticancer medications)
• Adults with advanced MM who already received but didn’t respond well to at least three prior anticancer treatments (given alone)

• Infusion-related reactions
• Decreases in blood cell counts
• Cold-like symptoms (upper respiratory infection)
• Diarrhea
• Constipation
• Nerve damage causing tingling, numbness or pain
• Tiredness
• Swollen hands, ankles, or feet
• Nausea
• Cough
• Fever
• Shortness of breath
• Feeling weak

• Infusion-related reactions
• Changes in lab test results for blood transfusions
• Lower white blood cell counts (risk of infection)
• Lower platelet counts (risk of bleeding)
• Changes in test results for treatment response
• Harm to unborn baby

Sarclisa (isatuximab or isatuximab-irfc) is a monoclonal antibody that’s used to treat a type of blood cancer called multiple myeloma. It helps stop the cancer from growing and spreading. Sarclisa (isatuximab) is given as an intravenous infusion through your vein (IV). It’s typically given together with two other medications to treat cancer. Sarclisa (isatuximab) might cause side effects such as infusion-related reactions, low white blood cell counts, and diarrhea.

• Multiple myeloma in adults who’ve received at least two previous therapies, given together with Pomalyst (pomalidomide) and dexamethasone
• Multiple myeloma in adults who’ve received one to three previous therapies, given together with Kyprolis (carfilzomib) and dexamethasone

• Lower red blood cell counts (up to 99%)
• Lower white blood cell counts (up to 96%)
• Lower platelet counts (up to 94%)
• Upper respiratory infection (e.g., sinus infections, bronchitis; up to 67%)
• Infusion-related reaction (up to 46%)
• Tiredness (42%)
• Higher blood pressure (37%)
• Pneumonia (up to 36%)
• Diarrhea (up to 36%)
• Trouble breathing (up to 29%)
• Cough (23%)

• Infusion-related reactions
• Low white blood cell counts
• New cancers
• Changes to other lab test results
• Harm to unborn baby